Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) for THRV-1257. THRV-1257 is being investigated for the treatment of advanced Anaplastic Thyroid Cancer (ATC), including those patients with the common BRAF mutation V600E. The first in human study will determine the optimal dosing of THRV-1257 in patients with solid tumors, followed by treatment in combination with approved cancer therapies.

Lizzy's journey with Long QT Syndrome began at birth when a nurse noticed her low heartbeat, leading to comprehensive monitoring and the identification of her arrhythmia. She was immediately transported to the Children's Hospital of Philadelphia, where she was diagnosed with Long QT Syndrome Type 3.

Join us as we introduce Marc Vidal, our Senior Director of Product & Process Development at Thryv. Discover Marc’s journey in the sciences, how it lead him to be the first employee to join the Thryv team, and learn how he consistently works to #berelentless in pursuit of innovation!

The family hopes that by sharing their story, people will evaluate how prepared they are for a cardiac event. Whether it's through CPR training or having AEDs in schools, they want to change the narrative of "it won't happen to me".

While we await results from our initial proof of efficacy study this summer in Long QT Syndrome, we are able to accelerate a number of pipeline initiatives thanks to this new investment from IQ.

Curious about the behind-the-scenes of Thryv's oncology program development? Meet Shannon Hewgill, our Research Associate who's work in the lab is helping develop the oncology program from the ground up.

Two weeks after doctors told her parents she was the “picture of health”, Abrielle suffered a sudden cardiac arrest. Fortunately, her father was able to perform CPR until emergency personnel arrived.

Rob’s message to the Long QT community is to not fear their diagnosis. He lives his life by the same philosophy he applies in racing: Control what you can control.

In our new series, ‘Inside Thryv - Conversations with Employees,’ we sit down with our team members to learn about their roles and how they help drive our mission forward. First up is Thryv’s President & Chief Development Officer, Debra Odink!

Lizzie hopes sharing her experiences raising a child with an ICD and diagnosed Long QT Type 15, she will reach people it can help.

The SADS Foundation is working with companies almost ready to recruit participants for first-of-their-kind clinical trials. But first, they need to learn more about the SADS community through this ten-minute survey so they can help connect you to research studies.

Three of our team were invited to join Dr. Michael Ackerman as part of the SADS Live program. We invite you to watch this interview to learn more about our passionate team and progress, what the next steps are as we move into clinical studies, and what we are doing to challenge the current LQTS treatments.

2022 was a big year for Thryv Therapeutics, and 2023 is shaping up to be even bigger. Debra Odink, President & Chief Development Officer, shares her wrap-up of the year.

Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers.

Two fireside chats by Mr. Paul F. Truex CEO on Thryv’s progress with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.

Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago

We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.

We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.

Dr. Campeau will collaborate with Dr. McDonnell and his research team at Duke University to evaluate SGK1 inhibitors as potential treatments for people with breast and prostate cancer.

A major objective after our Series A financing, has been to enrich our Board with experienced, respected and highly accomplished drug development executives as we advance our clinical programs.